✉news HealthMedicine first seen 2 d ago, last 1 d ago, peak #6
Vivek Subbiah to Lead Early-Phase Drug Development at Perlmutter Cancer Center
Original: Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs
NYU Langone Health's Perlmutter Cancer Center has appointed Vivek Subbiah, MD, to lead its early-phase drug development and rare cancer programs. Subbiah, known for his work in early-stage oncology trials and precision medicine, will oversee efforts to bring experimental therapies to patients. The move is part of the center's push to expand clinical trial capabilities.
Why now: The appointment of a prominent oncology researcher signals Perlmutter Cancer Center's ambition in experimental cancer therapies, drawing professional attention.
Vivek SubbiahPerlmutter Cancer CenterNYU Langone Health
Rank over time, top of the chart is #1. 7 snapshots from 2 d ago to 1 d ago.
Evidence
- Perlmutter Cancer Center Taps Vivek Subbiah, MD, to Lead Early-Phase Drug Development and Rare Cancer Programs · NYU Langone Health
API: https://socialmediatrends-api.osmike.com/v1/trends/3255777